Mission

ICER's mission is to lead innovation in comparative effectiveness research through methods that integrate considerations of clinical benefit and economic value.  Through a unique collaboration with patients, clinicians, manufacturers, insurers and other healthcare stakeholders, ICER develops tools to support patient decisions and medical policy that share the goal of achieving maximum value for every healthcare dollar.

Staff Only

Remember Me
TwitterLinkedinFacebookFeed
Advisory Board Membership and Conflict of Interest Policy

ICER has established a diverse Advisory Board to inform the strategic direction of ICER’s work.  Advisory board members represent all the major stakeholder groups in comparative effectiveness research, including purchasers, payers, device and pharmaceutical manufacturers, providers, patients, and experts in health policy and ethics.  ICER relies on its Advisory Board to provide frank and constructive feedback on ICER’s strategic direction and operational priorities.

Membership on the Advisory Board is solely at the invitation and discretion of ICER’s senior management team.  While many Advisory Board member companies provide ICER with unrestricted financial support, financial support of ICER is not a guarantee, nor a requirement, of Advisory Board membership.  

In order to avoid any potential conflict of interest with the mission of ICER, ICER has adopted the following statement to guide its Advisory Board on issues of potential influences on judgment, disclosure and recusal.  

  • The Advisory Board does not govern ICER in any way.  The function of the Advisory Board is solely to provide perspective and advice to ICER staff on how ICER can best fulfill its mission. 
  • Because there are organizations represented on the Board who compete in the healthcare marketplace, ICER staff and all Advisory Board members will refrain from any discussion that could provide the basis for an inference that members considered any action that might restrain trade in any way.
  • At no time will the Advisory Board discuss the scientific or methodological merits of any specific technology appraisal.  However, if a topic arises during an Advisory Board meeting that could have competitive repercussions in a therapeutic area in which manufacturing industry representatives compete, they must disclose to the Board that they have a potential conflict and leave the room during the remainder of that discussion.  Meeting minutes will document the recusal.  Given that the Advisory Board is removed from discussions that involve consideration of specific interventions it will be extremely unlikely that this form of recusal would be required at any time.